ZA201706392B - Maleate salts of a b¿raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore - Google Patents
Maleate salts of a b¿raf kinase inhibitor, crystalline forms, methods of preparation, and uses thereforeInfo
- Publication number
- ZA201706392B ZA201706392B ZA2017/06392A ZA201706392A ZA201706392B ZA 201706392 B ZA201706392 B ZA 201706392B ZA 2017/06392 A ZA2017/06392 A ZA 2017/06392A ZA 201706392 A ZA201706392 A ZA 201706392A ZA 201706392 B ZA201706392 B ZA 201706392B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- methods
- kinase inhibitor
- crystalline forms
- raf kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076639 | 2015-04-15 | ||
| PCT/CN2016/079251 WO2016165626A1 (en) | 2015-04-15 | 2016-04-14 | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201706392B true ZA201706392B (en) | 2019-05-29 |
Family
ID=57125563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/06392A ZA201706392B (en) | 2015-04-15 | 2017-09-21 | Maleate salts of a b¿raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10351559B2 (OSRAM) |
| EP (2) | EP4119559A1 (OSRAM) |
| JP (3) | JP7320741B2 (OSRAM) |
| KR (2) | KR102643609B1 (OSRAM) |
| CN (2) | CN107531682B (OSRAM) |
| AU (1) | AU2016248376B2 (OSRAM) |
| CA (1) | CA2981746C (OSRAM) |
| EA (1) | EA035680B1 (OSRAM) |
| IL (2) | IL255555B (OSRAM) |
| MX (1) | MX381053B (OSRAM) |
| NZ (1) | NZ735715A (OSRAM) |
| SG (1) | SG11201707984TA (OSRAM) |
| TW (4) | TWI876835B (OSRAM) |
| WO (1) | WO2016165626A1 (OSRAM) |
| ZA (1) | ZA201706392B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1888548E (pt) | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
| JP5885670B2 (ja) | 2009-12-11 | 2016-03-15 | アルデイラ セラピューティクス， インコーポレイテッド | 黄斑変性の処置のための組成物および方法 |
| EP3124472B1 (en) | 2011-12-31 | 2018-07-25 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
| JP6514114B2 (ja) | 2013-01-23 | 2019-05-15 | アルデイラ セラピューティクス， インコーポレイテッド | 毒性アルデヒド関連疾患および処置 |
| CN107531682B (zh) * | 2015-04-15 | 2021-05-04 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CN110494166B (zh) | 2017-05-02 | 2022-11-08 | 诺华股份有限公司 | 组合疗法 |
| EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| LT3873894T (lt) * | 2018-10-31 | 2023-06-26 | Les Laboratoires Servier | Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| BR112021016921A2 (pt) * | 2019-03-15 | 2021-11-03 | Forma Therapeutics Inc | Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb) |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| EP3962894A4 (en) | 2019-05-02 | 2023-01-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
| BR112021022335A2 (pt) | 2019-05-13 | 2021-12-28 | Novartis Ag | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| KR20230048476A (ko) * | 2020-04-03 | 2023-04-11 | 베이진 리미티드 | 암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여 |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5111113B2 (ja) | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| BRPI0619514A2 (pt) * | 2005-12-08 | 2011-10-04 | Millennium Pharm Inc | compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos |
| WO2007136572A2 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| EP2057141B1 (en) | 2006-08-23 | 2011-10-26 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008030448A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| KR20090130345A (ko) | 2007-05-04 | 2009-12-22 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물 |
| US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| EP3124472B1 (en) * | 2011-12-31 | 2018-07-25 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
| CN107531682B (zh) | 2015-04-15 | 2021-05-04 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
-
2016
- 2016-04-14 CN CN201680021109.0A patent/CN107531682B/zh active Active
- 2016-04-14 CA CA2981746A patent/CA2981746C/en active Active
- 2016-04-14 AU AU2016248376A patent/AU2016248376B2/en active Active
- 2016-04-14 TW TW113101605A patent/TWI876835B/zh active
- 2016-04-14 EA EA201792254A patent/EA035680B1/ru unknown
- 2016-04-14 SG SG11201707984TA patent/SG11201707984TA/en unknown
- 2016-04-14 JP JP2017553956A patent/JP7320741B2/ja active Active
- 2016-04-14 NZ NZ735715A patent/NZ735715A/en unknown
- 2016-04-14 MX MX2017013219A patent/MX381053B/es unknown
- 2016-04-14 TW TW110125410A patent/TWI792406B/zh active
- 2016-04-14 EP EP22179294.8A patent/EP4119559A1/en active Pending
- 2016-04-14 TW TW112101259A patent/TWI832668B/zh active
- 2016-04-14 CN CN202110419671.1A patent/CN113307805A/zh active Pending
- 2016-04-14 US US15/565,807 patent/US10351559B2/en active Active
- 2016-04-14 WO PCT/CN2016/079251 patent/WO2016165626A1/en not_active Ceased
- 2016-04-14 KR KR1020177033101A patent/KR102643609B1/ko active Active
- 2016-04-14 KR KR1020247006890A patent/KR20240049684A/ko active Pending
- 2016-04-14 EP EP16779601.0A patent/EP3283486B1/en active Active
- 2016-04-14 TW TW105111715A patent/TWI736531B/zh active
-
2017
- 2017-09-21 ZA ZA2017/06392A patent/ZA201706392B/en unknown
- 2017-11-09 IL IL255555A patent/IL255555B/en unknown
-
2021
- 2021-01-22 JP JP2021009106A patent/JP7383652B2/ja active Active
- 2021-10-31 IL IL287740A patent/IL287740B2/en unknown
-
2023
- 2023-11-08 JP JP2023190552A patent/JP2024012540A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201706392B (en) | Maleate salts of a b¿raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
| HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
| IL279258B (en) | tyrosine kinase inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| ZA201701633B (en) | Compounds and compositions as raf kinase inhibitors | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| PL3372607T3 (pl) | Postać krystaliczna inhibitora kinazy btk i sposób jego otrzymywania | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| ZA201802267B (en) | Salts of a pim kinase inhibitor | |
| IL251197A0 (en) | The crystal forms of tyrosine kinase inhibitors and their salts | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| IL252986B (en) | 5,3-diaminopyrazole kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors | |
| HK1235781A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| GB201522245D0 (en) | Compounds useful as kinase inhibitors |